Professional Documents
Culture Documents
Respi Copd
Respi Copd
BRONCHIECTASIS
• Chronic, irreversible dilation of the
bronchi and bronchioles that results
from destruction of muscles and elastic
MANAGEMENT OF PATIENTS WITH connective tissue
CHRONIC PULMONARY DISEASE
CHRONIC BRONCHITIS
• Defined as the presence of cough and
sputum production for at least 3
months in each of 2 consecutive years
CLINICAL MANIFESTATIONS
• Chronic cough
• Production of purulent sputum
• Clubbing of fingers
• Repeated episodes of respiratory
infection
MEDICAL MANAGEMENT
• Promote bronchial drainage
EMPHYSEMA • Clear excessive secretions
• Abnormal distention of the airspaces • Prevent or control infection and
beyond the terminal bronchioles and inflammation
destruction of the walls of the alveoli
PHARMACOLOGIC THERAPY
• Antibiotics – antimicrobial therapy
choice on empiric coverage is
prescribed initially
• Vaccination against Influenza and
Pneumococcal Pneumonia
• Nebulized mucolytics – hypertonic
CLINICAL MANIFESTATIONS
saline improves airway clearance
• Chronic cough, sputum production and
dyspnea
• Weight loss is common
1
NCM112j -RESPI
Chronic Obstructive Pulmonary Disease
ASTHMA
• Characterized by chronic airway
inflammation that causes
hyperresponsiveness, mucosal edema,
mucus production
CLINICAL MANIFESTATIONS
• Cough
• Chest tightness
• Wheezing
• Dyspnea
MEDICAL MANAGEMENT
• Prevent impairment of lung function by
minimizing symptoms, preventing
exacerbation
PHARMACOLOGIC THERAPY
• Quick-relief medications - for
immediate treatment of asthma
symptoms and exacerbation, relax
smooth muscle (Albuterol,
Levalbuteorl, Pirbuterol)
• Anticholinergic (Ipratropium) -
may be used to patients who do not
tolerate short acting beta 2 adrenergic
agonists
• Long acting medications - to
achieve and maintain control of
persistent asthma (Corticosteroids)